Clinical Trial - Biomaker-Targeted - Recurrent Stage IV Squamous Cell Lung Cancer

This clinical trial is run by National Cancer Institute to apply Biomarker-Targeted second-line therapy to recurrent stage IV squamous cell lung cancer treatment.

Trial Name:Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer

Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 900 locations

Cancer biomakers and targeted therapies are rationalized and individualized cancer therapy. Cancer biomarkers are the measurable molecular changes to either cancerous or normal tissues of patients. A reliable biomarker can be used for cancer diagnosis, risk and prognosis assessments, and for the surveillance of treatment effectiveness. More importantly, some, but not all, biomarkers can be exploited as therapeutic targets.

Please fine details of the clinical trial at



* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.